Breaks Categories: Stock Spotlights

TuesdayAug 17, 2021 2:51 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Standing Distinct in Psychedelic-Derived Treatments Space

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is focused on driving significant innovation with its drug development pipeline. Tryp is leveraging its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program in the development of treatments for chronic pain indications including fibromyalgia, phantom limb pain and complex regional pain syndrome. In addition, the company is preparing to initiate a phase 2a clinical trial for eating disorders including binge eating and hypothalamic obesity. “With the growing popularity and proliferation of psychedelics, many companies are pursuing therapeutic indications with the compounds,” reads a recent article discussing Tryp’s positioning. “However, very few have initiated phase 2a studies. Tryp Therapeutics…

Continue Reading

FridayAug 13, 2021 2:30 pm

BioMedNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) State-of-the-Art IoT Products Provide Holistic View for Optimal Research

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is standing by to provide a wealth of smart devices, artificial intelligence and an integrated platform that will fully support the U.S. as it explores the benefits, risks and effects of cannabis. “U.S. researchers can benefit from RYAH Group’s state-of-the-art IoT suite of products. The technology collects, analyzes and leverages objective data throughout the research process. As a result, the company boasts one of the largest plant-based medicine databases globally with 200,000 plus registered users. The company’s ecosystem of products allows data to be collected from seed…

Continue Reading

ThursdayAug 12, 2021 12:51 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Bringing Groundbreaking Tech to Push Boundaries in Neurology Space

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, appears poised for rapid growth as the application space for EEG-based solutions expands. “With its current and future products, including disposable EEG headsets for neurological patients, long-term monitoring solutions, and AI-empowered technology for recording brain activity, the company appears well-placed within the growing brain monitoring space,” reads a recent article. This comes as the brain-computer interface (“BCI”) field is growing rapidly, representing one of the main driving factors behind the expansion of EEG technology. It is a promising approach to overcoming paralysis by decoding brain signals…

Continue Reading

WednesdayAug 11, 2021 2:16 pm

BioMedNewsBreaks – Why AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is focused on early cancer screening and detection. With an aim of changing the way people approach cancer screening, the company develops, distributes and deploys accessible early disease detection devices. “AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance,” reads a recent article discussing the company. “Cancer Differentiation Analysis (‘CDA’) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins…

Continue Reading

FridayAug 06, 2021 2:19 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Positioned to be at Center Stage of Neurological Diagnostics Space

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, appears well-positioned to offer solutions for the growing market need in the post-pandemic world. “As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered from COVID-19 is mounting,” reads a recent article. As such, the market for BRSF’s innovative products appears to expand. “It is becoming increasingly clear that neurological diagnostics will be at the center of the future post-COVID-19 health care of patients who suffered from the infection. As a commercial stage health care company…

Continue Reading

FridayAug 06, 2021 1:42 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Paving Way for Better Outcomes of Plant-Based Treatments

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is known for its high-quality information and digital health care analytics through which it is positively impacting the future treatment of patients for various medical conditions worldwide. RYAH is partnering with the University of Milan and companies like Medical Kiwi to drive innovation and deliver cutting-edge medical solutions, as well as providing the necessary dose-measuring devices to an oncology clinic in the U.K. “RYAH Group is paving the way for a better understanding and better outcomes of plant-based treatments globally,” reads a recent article. “This is achieved…

Continue Reading

FridayAug 06, 2021 12:12 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Poised to Establish New Standard in Bladder Cancer Visualization

Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed the i/Blue Imaging System(TM), an innovative technology designed to significantly improve the way surgeons visualize cancerous cells for more accurate bladder resection. The patented technology, which has entered the manufacturing stage and is expected to be completed in 2022, allows for white and blue light images to be projected side-by-side simultaneously, enabling better surgical technique. It will also attach to most endoscopes currently on the market, protecting hospitals’ investment in instruments they already own and enabling their adoption of blue light cystoscopy at significant cost savings. A recent article reads, “With the…

Continue Reading

FridayJul 30, 2021 12:03 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Developing, Delivering New Generation of MedTech Solutions for Brain Diagnostics Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, recently announced its entry into a definitive merger agreement to acquire Piezo Motion Corp., a leading innovator of high-precision piezoelectric motion technology. The merger is anticipated to expand the market footprint both for Brain Scientific and Piezo Motion, as well as the potential to deliver innovative technologies to high-growth sectors. Dr. Baruch Goldstein, founder of Brain Scientific, was quoted in a recent article as saying, “Together, we plan to achieve rapid expansion while delivering and developing the new generation of MedTech solutions for the brain diagnostics…

Continue Reading

WednesdayJul 28, 2021 12:09 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Clear Opportunity to Bring Impactful Therapy to GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. Over recent months, the company has achieved several milestones demonstrating its operational, financial and strategic strengths and continuous de-risking of its lead candidate Berubicin clinical program. “The company has begun a pivotal Phase 2 clinical trial evaluating the efficacy and safety of Berubicin for recurrent adult glioblastoma multiforme (‘GBM’). Enrollment in the clinical trial is already underway, with patient dosing set to begin in Q3 2021,” reports an article discussing the status of…

Continue Reading

TuesdayJul 27, 2021 3:44 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expanded Customer Base, Multiple Collaborations, Fulfillment of Researchers’ Needs

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new good manufacturing practices (“GMP”) laboratories. For Soluble Biotech, the GMP facility ramps up its formulation solutions and stability services so the company can rapidly provide clinical-trial-ready formulations to its customers. The lab will also be utilized to produce proprietary media used in its chromatography kits. A recent article reads, “Dr. Larry DeLucas, VP of Operations at Predictive Oncology, said he…

Continue Reading